Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scorpius Holdings Inc SCPX

Healthcare Biotechnology
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio... see more

Recent & Breaking News (NYSEAM:SCPX)

NightHawk Biosciences Provides Q1 2023 Business Update

GlobeNewswire May 15, 2023

NightHawk Biosciences Provides 2022 Year End Business Update

GlobeNewswire March 31, 2023

NightHawk Biosciences Provides Third Quarter 2022 Business Update

GlobeNewswire November 14, 2022

Nighthawk Biosciences' Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

GlobeNewswire October 21, 2022

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

GlobeNewswire August 23, 2022

NightHawk Biosciences Provides Second Quarter 2022 Business Update

GlobeNewswire August 10, 2022

NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services

GlobeNewswire June 13, 2022

NightHawk Biosciences Provides First Quarter 2022 Business Update

GlobeNewswire May 16, 2022

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

GlobeNewswire May 10, 2022

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open Today

GlobeNewswire May 3, 2022

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

GlobeNewswire April 27, 2022

Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics

GlobeNewswire April 20, 2022

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

GlobeNewswire April 19, 2022

REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments

GlobeNewswire April 18, 2022

Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

GlobeNewswire April 18, 2022

Heat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

GlobeNewswire April 14, 2022

Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

GlobeNewswire March 25, 2022

Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company

GlobeNewswire March 23, 2022

Heat Biologics Provides Year-End 2021 Business Update

GlobeNewswire March 14, 2022

Heat Biologics Announces Planned Transfer to the NYSE American

GlobeNewswire February 2, 2022